

Please type a plus sign (+) inside this box +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known Application Number 09/939,472 Conf. #2671 Filing Date August 24, 2001 First Named Inventor Matthew J. During Group Art Unit 1646 Examiner Name O. Chernyshev Attorney Docket Number 104036-17	
Sheet	1	of	1

U. S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	U. S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² <i>(if known)</i>			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Office ³	Number ⁴	Kind Code ⁵ <i>(if known)</i>			
OC			EP 0 620 008		Iliana Gozes, et al	10/19/1994	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T ²
OC		Joshi, A. B., et al, "The Degradation Pathways of Glucagon in Acidic Solutions" <i>International Journal of Pharmaceutics</i> , (2000) Vol. 203, No. 1-2; pp. 115-125.		

Examiner Signature <i>O. Chernyshev</i>	Date Considered <i>09/29/03</i>
--	------------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute Form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet 1 of 1

Complete if Known

Application Number	09/939,472
Filing Date	August 24, 2001
First Named Inventor	DURING, Matthew
Group Art Unit	1646
Examiner Name	Oiga Chernysh v
Attorney Docket Number	DUR01-NP003

OTHER PRIOR ART "NON PATENT LITERATURE DOCUMENTS"

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	T ²
	AA	ALVAREZ, E., RONCERO, I., CHOWEN, J., THORENS, B., & BLAZQUEZ, E. "Expression of the Glucagon-like Peptide-1 Receptor Gene in Rat Brain" <i>J Neurochem</i> 1996, pp. 920-927, 66 (3).	
	AB	BUTEAU, J., RODUIT R., SUSINI, S., & PRENTKI, M. "Glucagon-like Peptide-1 Promotes DNA Synthesis, Activates Phosphatidylinositol 3-kinase and increases Transcription Factor Pancreatic and Duodenal Homeobox Gene 1 (PDX-1) DNA-binding Activity in beta (INS-1) Cells." <i>Diabetologia</i> 1999, pp. 856-864, 42.	
	AC	CHOWEN, J., DEFONSECA, R., ALVAREZ, E., NAVARRO, M., GARCIA-SEGURA, L., & BLAZQUEZ, E. "Increased Glucagon-like Peptide-1 Receptor Expression in Gila After Mechanical Lesion of the Rat Brain" <i>Neuropeptides</i> 1999, pp. 212-215, 33 (3).	
	AD	DRUCKER, D., PHILIPPE, J., MOJSOV, S., CHICK, W., & HABENER J. "Glucagon-like Peptide 1 Stimulates Insulin Gene Expression and Increases Cyclic AMP Levels in a Rat Islet Cell Line." <i>Proc. Natl. Acad. Sci. USA</i> 1987, pp. 3434-3438, 84 (May).	
	AE	GALLWITZ, B., ROFETEN T., MORYS-WORTMANN, C., MENTLEIN, R., SIEGEL, E., SCHMIDT, W. "GLP-1 Analogues Resistant to Degradation by Dipeptidyl-Peptidase IV in Vitro." <i>Regulatory Peptides</i> 2000, pp. 103-111, 86.	
	AF	JIN, S., HAN, V., SIMMONS, J., TOWLE, A., LAUDER, J., & LUND, P. "Distribution of Glucagonlike Peptide I (GLP-1) Glucagon and Glucagonin in the Rat Brain: An immunocytochemical Study." 1988, pp. 519-532, 271 (4).	
	AG	MERCHENTHALER, I., LANE, M., & SHUGHRIUE, P. "Distribution of Pre-Pro-Glucagon and Glucagon-Like Peptide-1 Receptor Messenger RNA's in the Rat Central Nervous System." <i>J Comp Neurol</i> 1999, pp. 261-280, 403.	
	AH	SCHROCK, L., BROWN, T., MACLUSKY, N., BRUBAKER, P., AUERBACH, A., JOYNER, A., & DRUCKER D. "Glucose Intolerance but Normal Satiety in Mice with a Null Mutation in the Glucagon-like Peptide 1 Receptor Gene." 1996, pp. 1254-1258, Jan 11, 403 (2).	
	AI	STOFFERS, D., KIEFFER, T., HUSSAIN, M., DRUCKER, D., BONNER-WEIR, S., HABENER, J., & EGAN, J. "Insulinotropic Glucagon-like Peptide 1 Agonists Stimulate Expression of Homeodomain Protein IDX-1 and Increase Islet Size in Mouse Pancreas." <i>Diabetes</i> 2000, pp. 741-748, 49 (5) May.	
	AJ	TSENG, C., ZHANG, X., & WOLFE, M. "Effect of GIP and GLP-1 Antagonists on Insulin Release in the Rat." <i>Am J. Physiol</i> 1999, pp. E1049-1054, 49 (5) May.	
	AK	TURTON, M., O'SHEA, D., GUNN, I., BEAK, S., EDWARDS, C., MEERAN, K., CHOI, S., TAYLOR, G., HEATH, M., LAMBERT, P., WILDING, J., SMITH, D., GHATEI, M., HERBERT, J., & BLOOM, S. "A Role for Glucagon-like Peptide-1 in the Central Regulation of Feeding." <i>Nature</i> 1996, pp. 69-72, 379, Jan 4.	
	AL	WHEELER, M., LU, M., DILLON, J., LENG, X., CHEN, C., & BOYO, A. "Functional Expression of the Rat Glucagon-like Peptide-1 Receptor, Evidence for Coupling to Both Adenylate Cyclase and Phospholipase-C." <i>Endocrinology</i> 1993, pp. 57-62, 133 (1) Jul.	
	AM	ZHOU, J., WANG, X., PINEYRO, M., & EGAN, J. "Glucagon-like Peptide 1 and Exendin-4 Convert Pancreatic AR42J Cells into Glucagon-and-Insulin-Producing Cells." <i>Diabetes</i> 1999, pp. 2358-2368, 48 (12) Dec.	

RECEIVED

JUN 25 2002

Examiner Signature	Date Considered	09/24/03
--------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through initial if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for Patents Washington, DC 20231.